AOD 9604
Also known as: HGH Fragment 176-191 modificado
Molecular Identifiers
Molecular Formula
C78H123N23O23S2
CAS Number
221231-10-3
PubChem CID
71300630Molecular Weight
1815.1 Da
Overview
Modified HGH fragment (amino acids 176-191) that acts on fat metabolism without affecting blood glucose or insulin levels. Promotes lipolysis and inhibits lipogenesis.
The clinical appeal of AOD 9604 lies in isolating the lipolytic action of GH without anabolic effects and without impact on glucose, insulin, or IGF-1. Preclinical studies have shown increased lipolysis via the beta-3 adrenergic receptor and inhibition of lipogenesis, which makes it attractive for body recomposition protocols, especially combined with a caloric deficit and fasted cardio.
The peptide was originally developed as an anti-obesity drug candidate but did not obtain approval as a medication — phase 2 trials failed to meet meaningful primary endpoints for weight loss in humans. It is now widely dispensed by compounding pharmacies as off-label use, and in some countries it is registered as a cosmetic ingredient for topical use. The short half-life justifies daily administration.
Among GH fragments, it is most often compared with HGH Fragment 176-191: both derive from the C-terminal portion of GH and aim to isolate the lipolytic effect without the anabolic effects of the whole hormone, but AOD 9604 is a modified version (Tyr-hGH 177-191) with an added N-terminal tyrosine for stability, while HGH Frag 176-191 is the unmodified native sequence.
YLRIVQCRSVEGSCGF Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe Half-life
~30 minutes
Administration Route
Subcutaneous
Category
Metabolic & Fat Loss
Mechanism of Action
- Stimulation of lipolysis via beta-3 adrenergic receptor
- Inhibition of lipogenesis
- No effect on blood glucose or IGF-1
- Mimics the lipolytic action of GH without anabolic effects
Dosage Protocol
Data compiled from the literature. This does not constitute medical advice.
| Parameter | Value |
|---|---|
| Dose | 300-600 mcg per injection |
| Frequency | Once daily |
| Timing | Morning, fasted |
| Duration | 12+ weeks |
Reported Side Effects
Adverse effects described in the literature. Severity and frequency vary between individuals.
- Injection site pain
- Mild headache
- Local redness
Product Properties
| Purity | >98% |
| Appearance | White lyophilized powder |
| Solubility | Soluble in water and bacteriostatic water |
| Source | Solid-phase peptide synthesis (SPPS) |
| Storage | Lyophilized: -20°C for up to 2 years, 2-8°C for up to 6 months. Reconstituted: 2-8°C for up to 4 weeks. Protect from light and moisture. Avoid repeated freeze-thaw cycles. |
Presentations & Preparation
Vials of AOD 9604 found in the research market:
Reconstitution
- Diluent: Bacteriostatic water
- Volume: 2 ml per 5 mg vial
- Slowly inject the diluent along the vial wall
- Gently swirl until fully dissolved
- Never shake
Storage
- Lyophilized: Refrigerated 2-8°C
- Reconstituted: Refrigerated 2-8°C (up to 30 days)
- Protect from direct light
- Do not freeze after reconstitution
Scientific Studies
Published studies on AOD 9604.
Related Peptides
5-Amino-1MQ
50 mg per capsule · 1-2 times daily
Adipotide
0.03 mg/kg body weight (Phase 1 trial starting dose) · Once daily
AICAR
0.1 mg/kg/min by intravenous infusion (CABG trial dose) · Single continuous infusion
Cagrilintide
1.2-4.5 mg per week (subcutaneous) · Once weekly
Dulaglutide
0.75-4.5 mg per week (subcutaneous) · Once weekly
Exenatide
5-10 mcg per injection (subcutaneous) · Twice daily (Byetta) or once weekly (Bydureon)